gastric inhibitory polypeptide

Summary

Summary: A gastrointestinal peptide hormone of about 43-amino acids.

Top Publications

  1. ncbi Biology of incretins: GLP-1 and GIP
    Laurie L Baggio
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 132:2131-57. 2007
  2. ncbi Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes 50:609-13. 2001
  3. ncbi The biology of incretin hormones
    Daniel J Drucker
    Department of Medicine, The Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Ontario M5G 2C4, Canada
    Cell Metab 3:153-65. 2006
  4. pmc The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes
    Hans Juergen Woerle
    Department of Internal Medicine II, Clinical Research Unit, Clinical Center of the Ludwig Maximilians University, Campus Grosshadern, Munich, Germany
    Diabetes 61:2349-58. 2012
  5. pmc Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes
    BLANDINE LAFERRERE
    St Lukes Roosevelt Hospital, Obesity Research Center, 1111 Amsterdam Avenue, New York, NY 10025, USA
    J Clin Endocrinol Metab 93:2479-85. 2008
  6. pmc Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes
    BLANDINE LAFERRERE
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 1111 Amsterdam Ave, New York, NY 10025, USA
    Diabetes Care 30:1709-16. 2007
  7. ncbi Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    H E Parker
    Cambridge Institute for Medical Research, Addenbrooke s Hospital, Wellcome Trust MRC Building, Hills Road, Cambridge CB2 0XY, UK
    Diabetologia 52:289-98. 2009
  8. pmc Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans
    Meena Asmar
    1Department of Clinical Physiology Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark
    Diabetes 59:2160-3. 2010
  9. pmc Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects
    Jing Ma
    University of Adelaide, Discipline of Medicine, Royal Adelaide Hospital, North Terr, Adelaide SA 5000, Australia
    Am J Physiol Gastrointest Liver Physiol 296:G735-9. 2009
  10. pmc Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Surg Obes Relat Dis 3:597-601. 2007

Research Grants

Detail Information

Publications279 found, 100 shown here

  1. ncbi Biology of incretins: GLP-1 and GIP
    Laurie L Baggio
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 132:2131-57. 2007
    ..Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes...
  2. ncbi Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Diabetes 50:609-13. 2001
    ....
  3. ncbi The biology of incretin hormones
    Daniel J Drucker
    Department of Medicine, The Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Ontario M5G 2C4, Canada
    Cell Metab 3:153-65. 2006
    ..This article summarizes current concepts of incretin action and highlights the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes...
  4. pmc The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes
    Hans Juergen Woerle
    Department of Internal Medicine II, Clinical Research Unit, Clinical Center of the Ludwig Maximilians University, Campus Grosshadern, Munich, Germany
    Diabetes 61:2349-58. 2012
    ..The absolute incretin effect is reduced in T2DM; its relative importance, however, appears to be increased, highlighting its role as an important amplifier of first-phase ISR in T2DM...
  5. pmc Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes
    BLANDINE LAFERRERE
    St Lukes Roosevelt Hospital, Obesity Research Center, 1111 Amsterdam Avenue, New York, NY 10025, USA
    J Clin Endocrinol Metab 93:2479-85. 2008
    ..Gastric bypass surgery (GBP) results in rapid weight loss, improvement of type 2 diabetes (T2DM), and increase in incretins levels. Diet-induced weight loss also improves T2DM and may increase incretin levels...
  6. pmc Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes
    BLANDINE LAFERRERE
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 1111 Amsterdam Ave, New York, NY 10025, USA
    Diabetes Care 30:1709-16. 2007
    ..We hypothesized that in obese patients with type 2 diabetes the impaired levels and effect of incretins changed as a consequence of RY-GBP...
  7. ncbi Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    H E Parker
    Cambridge Institute for Medical Research, Addenbrooke s Hospital, Wellcome Trust MRC Building, Hills Road, Cambridge CB2 0XY, UK
    Diabetologia 52:289-98. 2009
    ..The aim of this study was to generate transgenic mice with fluorescently labelled GIP-secreting K cells and to use these to investigate pathways by which K cells detect nutrients...
  8. pmc Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans
    Meena Asmar
    1Department of Clinical Physiology Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark
    Diabetes 59:2160-3. 2010
    ..In humans, however, there is no clear evidence of GIP effecting lipid metabolism. The present experiments were performed in order to elucidate the effects of GIP on regional adipose tissue metabolism...
  9. pmc Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects
    Jing Ma
    University of Adelaide, Discipline of Medicine, Royal Adelaide Hospital, North Terr, Adelaide SA 5000, Australia
    Am J Physiol Gastrointest Liver Physiol 296:G735-9. 2009
    ..4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline. We conclude that sucralose, delivered by intragastric infusion, does not stimulate insulin, GLP-1, or GIP release or slow gastric emptying in healthy humans...
  10. pmc Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Surg Obes Relat Dis 3:597-601. 2007
    ....
  11. ncbi Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity
    E Naslund
    Department of Surgery, Karolinska Institute, Stockholm, Sweden
    Obes Surg 8:253-60. 1998
    ..The aim of the present study was to examine the long-term effect of JIB on glucose metabolism...
  12. ncbi Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
    J de Heer
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200, Copenhagen N, Denmark
    Diabetologia 51:2263-70. 2008
    ..We examined whether the islet hormone somatostatin, which strongly inhibits glucagon secretion, is involved in this divergent behaviour...
  13. ncbi Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Regul Pept 114:115-21. 2003
    ....
  14. ncbi Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
    F C Lynn
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Diabetes 50:1004-11. 2001
    ..These data suggest that the decreased effectiveness of GIP in the VDF rat and in type 2 diabetes may be a result of a decreased receptor expression in the islet...
  15. pmc The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism
    Francesco Rubino
    IRCAD EITS, Strasbourg, France
    Ann Surg 240:236-42. 2004
    ..We speculated that if the mechanism of action of the RYGB involves an endocrine effect, then hormonal changes should occur early after surgery, prior to substantial body weight changes...
  16. ncbi Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat
    Shalea Piteau
    University of British Columbia, Department of Cellular and Physiological Sciences, Life Sciences Institute, 2350 Health Sciences Mall, Vancouver, BC, Canada
    Biochem Biophys Res Commun 362:1007-12. 2007
    ..These findings support the proposal that GIP receptor down-regulation in rodent T2DM is secondary to chronic hyperglycemia and that normalization of glycemia can restore GIP sensitivity...
  17. ncbi Impaired regulation of the incretin effect in patients with type 2 diabetes
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Copenhagen, Denmark
    J Clin Endocrinol Metab 96:737-45. 2011
    ..Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown...
  18. ncbi A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release
    Zhi Liang Chu
    Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California 92121, USA
    Endocrinology 149:2038-47. 2008
    ..These data also suggest that combined stimulation of incretin hormone release and protection against incretin hormone degradation may be an effective antidiabetic strategy...
  19. ncbi Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo
    Yukihiro Fujita
    Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    Am J Physiol Endocrinol Metab 296:E473-9. 2009
    ..Collectively, our findings do not support the concept that release of incretins from enteroendocrine cells is triggered by carbohydrates via a pathway identical to the sensation of "sweet taste" in the tongue...
  20. ncbi Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    Michael J Theodorakis
    Diabetes Section, Laboratory of Clinical Investigation, National Institute of Health, Baltimore, MD 21224, USA
    Am J Physiol Endocrinol Metab 290:E550-9. 2006
    ..Significant coexpression of the main incretin peptides occurs in human duodenum. L and K cells are present in equal numbers. New onset type 2 diabetes is associated with a shift to the L phenotype...
  21. ncbi Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice
    R A Pederson
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Diabetes 47:1046-52. 1998
    ..These observations suggest that upregulation of the GIP component of the enteroinsular axis, at the levels of GIP secretion and action, modifies the phenotype resulting from interruption of the insulinotropic activity of GLP-1 in vivo...
  22. ncbi DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
    Carolyn F Deacon
    Department of Biomedical Sciences, Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Front Biosci 13:1780-94. 2008
    ..This article focuses on DPP-4 inhibitors...
  23. ncbi Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
    M B Toft-Nielsen
    Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, DK-2650 Hvidovre, Denmark
    J Clin Endocrinol Metab 86:3717-23. 2001
    ..We conclude that the meal-related glucagon-like peptide-1 response in type 2 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes...
  24. ncbi Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion
    Yukihiro Fujita
    Laboratory of Molecular and Cellular Medicine, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Gastroenterology 138:1966-75. 2010
    ..Interestingly, a subset of enteroendocrine cells express both GIP and GLP-1. We sought to determine whether GIP also might be co-expressed with proglucagon in pancreatic alpha-cells...
  25. pmc GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes
    Nikolaos Mentis
    Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
    Diabetes 60:1270-6. 2011
    ..We studied whether GIP can alter the insulinotropic or glucagonostatic activity of GLP-1 in type 2 diabetic patients...
  26. ncbi Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo
    Erin B Ramshur
    Department of Internal Medicine, Division of Metabolism, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Cell Physiol 192:339-50. 2002
    ..These results provided unexpected insights into K-cell physiology and our experimental strategy could be easily modified to isolate/characterize additional EE cell populations...
  27. ncbi Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications
    N Irwin
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co Londonderry, BT52 1SA, UK
    Diabetologia 52:1724-31. 2009
    b>Gastric inhibitory polypeptide (GIP) is a physiological gut peptide secreted from the intestinal K-cells with well documented insulin-releasing actions...
  28. pmc Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide
    Thomas P J Solomon
    Department of Pathobiology, Cleveland Clinic, Cleveland, Ohio, USA
    Diabetes Care 33:1561-6. 2010
    ..The mechanisms by which lifestyle intervention may modify insulin secretion in type 2 diabetes have also not been examined but may involve the incretin axis...
  29. ncbi Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects
    Jerry R Greenfield
    Cambridge Institute for Medical Research and Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
    Am J Clin Nutr 89:106-13. 2009
    ..We previously demonstrated that glutamine is a potent stimulus of GLP-1 secretion in vitro...
  30. ncbi Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes 56:1951-9. 2007
    ..These results suggest that the reduced incretin effect is not a primary event in the development of type 2 diabetes, but rather a consequence of the diabetic state...
  31. pmc Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet
    Matthew C Althage
    Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, Saint Louis, MO 63110, USA
    J Biol Chem 283:18365-76. 2008
    ..In conclusion, studies using GIP/DT mice demonstrate an important role for K cells in the regulation of body weight and insulin sensitivity...
  32. ncbi Gastric inhibitory polypeptide: the neglected incretin revisited
    Juris J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    Regul Pept 107:1-13. 2002
    ..so-called "incretin effect" is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)...
  33. pmc Impact of glucose-dependent insulinotropic peptide on age-induced bone loss
    Ke Hong Ding
    Institute of Molecular Medicine and Genetics, Program in Regenerative Medicine, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Bone Miner Res 23:536-43. 2008
    ..We show for the first time that BMSCs express functional GIP receptors, that expression decreases with aging, and that elevations in GIP can prevent age-associated bone loss...
  34. ncbi Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal
    A B Goldfine
    Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 92:4678-85. 2007
    ..The etiology of the syndrome and metabolic characteristics remain incompletely understood. Recent studies suggest that levels of incretin hormones are increased after GB and may promote excessive beta-cell function and/or growth...
  35. ncbi On the physiology of GIP and GLP-1
    J J Holst
    Department of Medical Physiology, University of Copenhagen, 2200 Copenhagen N, Denmark
    Horm Metab Res 36:747-54. 2004
    ..Cardiovascular and neuroprotective actions of GLP-1 have also recently been reported. Regarding GIP, several lines of evidence suggest that GIP, in addition to its incretin effects, may affect lipid metabolism and promote lipid storage...
  36. ncbi Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    P V Højberg
    Department of Endocrinology, Hvidovre Hospital, Kettegaards Alle 30, DK 2650 Hvidovre, Denmark
    Diabetologia 52:199-207. 2009
    ..The aim of the present study was to investigate whether 4 weeks of near-normalisation of the blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes...
  37. pmc The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery
    James M Isbell
    Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Diabetes Care 33:1438-42. 2010
    ..RESEARCH METHODS AND DESIGN: A mixed meal was administered to nine subjects before and after RYGB (average 4 +/- 0.5 days) and to nine matched, obese subjects before and after 4 days of the post-RYGB diet...
  38. ncbi The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
    Asger Lund
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    Am J Physiol Endocrinol Metab 300:E1038-46. 2011
    ..Our results indicate that the intestinal hormones, GIP, GLP-1, and GLP-2, may play a role in the inappropriate glucagon response to orally ingested glucose in T2DM with, especially, GIP, acting to increase glucagon secretion...
  39. pmc Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
    Frederic Preitner
    Institute of Pharmacology and Toxicology, Lausanne, Switzerland
    J Clin Invest 113:635-45. 2004
    ....
  40. ncbi Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver
    Giovanni Musso
    Gradenigo Hospital, Turin, Italy
    Am J Clin Nutr 89:558-67. 2009
    ..We hypothesized that altered GIP secretion may contribute to the pathogenesis of NAFLD...
  41. ncbi Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes
    Soushou Lee
    Department of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, 1 5 8 Hatanodai, Shinagawa ku, Tokyo, Japan
    Endocr J 57:119-26. 2010
    ..We concluded that intact GLP-1 levels are comparable between non-diabetics and T2DM, suggesting that impaired insulin secretion in Japanese T2DM is not attributable to defect in GLP-1 secretion...
  42. ncbi Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion
    Mayumi Okawa
    Tsukuba Research Institute, Banyu Pharmaceutical Company, Ltd, Tsukuba, Ibaraki 300 2611, Japan
    Biochem Biophys Res Commun 390:377-81. 2009
    ..These findings suggest that synthesis and/or secretion of triglyceride-rich lipoproteins play an important role in the release of GIP. Moreover, DGAT1 may directly regulate the release of GLP-1 and PYY in L-cells...
  43. ncbi The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
    Andrea El-Ouaghlidi
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 92:4165-71. 2007
    ..the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP)...
  44. ncbi Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects
    S H Jacobsen
    Department of Endocrinology 541, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle 30, 2650 Hvidovre, Copenhagen, Denmark
    Obes Surg 22:1084-96. 2012
    ..We present a detailed analysis of the early hormone changes after RYGB in response to three different oral test meals designed to provide this information without causing side effects (such as dumping)...
  45. ncbi Extrapancreatic effects of GIP and GLP-1
    A Vella
    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester MN 55905, USA
    Horm Metab Res 36:830-6. 2004
    ..These effects may be of considerable importance in the treatment of postprandial hyperglycemia although they are not, strictly speaking, the result of a direct incretin effect on glucose metabolism...
  46. pmc Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2
    Su Jin Kim
    Department of Cellular and Physiological Sciences, Faculty of Medicine, University of British Columbia, 2350 Health Sciences Mall, Vancouver, B C V6T 1Z3, Canada
    Mol Cell Biol 28:1644-56. 2008
    ..The antiapoptotic effect of GIP in beta cells is therefore partially mediated through a novel mode of transcriptional regulation of Bcl-2 involving cAMP/PKA/AMPK-dependent regulation of CREB/TORC2 activity...
  47. ncbi The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction
    C Verdich
    Research Department of Human Nutrition, Centre for Advanced Food Studies, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark
    Int J Obes Relat Metab Disord 25:1206-14. 2001
    ..Previous studies have indicated that the secretion of the intestinal satiety hormone glucagon-like peptide-1 (GLP-1) is attenuated in obese subjects...
  48. pmc Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function
    Urd Kielgast
    Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark
    Diabetes 60:1599-607. 2011
    ....
  49. ncbi Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men
    Kazutaka Aoki
    Yokosuka Kyousai Hospital, Yokosuka, Japan
    Endocr J 57:673-7. 2010
    ..The administration of miglitol just before a meal, rather than after a meal, is recommended in view of the up-regulation of GLP-1...
  50. ncbi Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells
    K Moens
    Diabetes Research Center, Vrije Universiteit Brussel, Belgium
    Diabetes 45:257-61. 1996
    ..In conclusion, these data show that stimulation of glucagon, GLP-I, and GIP receptors in rat beta-cells causes cAMP production required for insulin release, while adenylate cyclase in alpha-cells is positively regulated by GIP...
  51. pmc Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain
    Randi Ugleholdt
    Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Biol Chem 286:44632-45. 2011
    ..The study supports a role of the adipocyte GIPr in nutrient-dependent regulation of body weight and lean mass, but it does not support a direct and independent role for the adipocyte or beta-cell GIPr in promoting adipogenesis...
  52. ncbi Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
    C F Deacon
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    J Endocrinol 172:355-62. 2002
    ..Total incretin secretion was reduced by DPP IV inhibition, suggesting the possibility of a feedback mechanism...
  53. ncbi Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients
    J Skrha
    Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
    Physiol Res 59:749-55. 2010
    ..Simple meal test could demonstrate impaired GIP secretion and delayed insulin secretion in Type 2 diabetic patients as compared to obese non-diabetic and non-obese healthy control individuals...
  54. ncbi Effects of fat supplementation on postprandial GIP, GLP-1, ghrelin and IGFBP-1 levels: a pilot study on adolescents with type 1 diabetes
    M Lodefalk
    Department of Women s and Children s Health, Karolinska Institutet, Stockholm, Sweden
    Horm Res Paediatr 73:355-62. 2010
    ..To compare the responses of GIP, GLP-1, ghrelin and IGFBP-1 between meals with different fat and energy content in adolescents with type 1 diabetes (T1DM) and to relate them to gastric emptying and glycaemia...
  55. ncbi Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    J Clin Endocrinol Metab 88:2706-13. 2003
    ....
  56. ncbi Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr Univ of Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Am J Physiol Endocrinol Metab 293:E849-56. 2007
    ..This has been attributed to the secretion and action of gastric inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)-1...
  57. ncbi Effect of aging and diabetes on the enteroinsular axis
    J Korosi
    Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
    J Gerontol A Biol Sci Med Sci 56:M575-9. 2001
    ..01; elderly control: 0.15 +/- 0.01; elderly diabetes: 0.15 +/- 0.01 DeltaOD/20 minutes; p <.05, elderly vs young). CONCLUSIONS: We conclude that normal aging and diabetes are associated with multiple changes in the enteroinsular axis...
  58. ncbi Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice
    Adriano Maida
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 137:2146-57. 2009
    ....
  59. ncbi GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations
    Carolyn F Deacon
    Dept of Medical Physiology, The Panum Institute, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
    Am J Physiol Endocrinol Metab 291:E468-75. 2006
    ..We conclude that, although GIP-(3-42) can weakly antagonize cAMP accumulation and insulin output in vitro, it does not behave as a physiological antagonist in vivo...
  60. pmc Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes--a role for the transcription factor NFAT and phosphodiesterase 3B
    Bilal Omar
    Department of Experimental Medical Sciences, Diabetes, Metabolism and Endocrinology, Biomedical Center, Lund University, Lund, Sweden
    Biochem Biophys Res Commun 425:812-7. 2012
    ..Given the established link between osteopontin and insulin resistance, our data suggest that GIP by stimulating osteopontin expression, also could promote insulin resistance in adipocytes...
  61. ncbi A mathematical model of the oral glucose tolerance test illustrating the effects of the incretins
    Patricia L Brubaker
    Department of Physiology, University of Toronto, Toronto, Canada
    Ann Biomed Eng 35:1286-300. 2007
    ....
  62. ncbi Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice
    Nigel Irwin
    School of Biomedical Sciences Research Institute, SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, UK
    Br J Nutr 108:46-56. 2012
    The effects of active immunisation with gastric inhibitory polypeptide (GIP) or (proline3)GIP-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy expenditure and cognition were examined in high-fat-fed mice...
  63. ncbi Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice
    Akira Shimotoyodome
    Biological Science Laboratories, Kao Corporation, Tochigi 321 3497, Japan
    Endocrinology 150:2118-26. 2009
    ..DAG promotes a lower GIP and thereby reduced insulin responses compared with triacylglycerol, which may differentially influence postprandial energy homeostasis...
  64. ncbi Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
    Juris J Meier
    Department of Medicine, St Josef Hospiital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:S220-4. 2004
    A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a characteristic of patients with type 2 diabetes...
  65. ncbi Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
    ..The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated...
  66. ncbi Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
    V A Gault
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Northern Ireland, UK
    Diabetologia 50:1752-62. 2007
    b>Gastric inhibitory polypeptide (GIP) receptor antagonism with (Pro(3))GIP improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure/function in ob/ob mice...
  67. ncbi Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
    Lisa Getty-Kaushik
    Obesity Research Center, Department of Molecular Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Obesity (Silver Spring) 14:1124-31. 2006
    ....
  68. pmc Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men
    Charlotte Brøns
    Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark
    J Physiol 587:2387-97. 2009
    ....
  69. pmc Nutrient detection by incretin hormone secreting cells
    Eleftheria Diakogiannaki
    Cambridge Institute for Medical Research and Department of Clinical Biochemistry, Addenbrooke s Hospital, Cambridge, UK
    Physiol Behav 106:387-93. 2012
    ..This review focuses on the molecular mechanisms to detect nutrient arrival in the gut that have been implicated within the incretin secreting cells...
  70. pmc Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism
    Burton M Wice
    Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 285:19842-53. 2010
    ..Xenin-25, or molecules that increase acetylcholine receptor signaling in beta-cells, may represent a novel approach to overcome GIP resistance and therefore treat humans with T2DM...
  71. ncbi Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, UK
    Diabetes 54:2436-46. 2005
    Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important incretin hormone secreted by endocrine K-cells in response to nutrient ingestion...
  72. ncbi Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects
    C Thomsen
    Aarhus Amtssygehus, Aarhus University Hospital, Denmark
    Am J Clin Nutr 69:1135-43. 1999
    ..A direct stimulatory effect of oleic acid on the secretion of glucagon-like peptide 1 (GLP-1) was shown in animal studies...
  73. pmc Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
    M Nagashima
    Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, 1 5 8 Hatanodai, Shinagawa ku, Tokyo 142 8666, Japan
    Diabetologia 54:2649-59. 2011
    ..We investigated the possibility that glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can prevent the development of atherosclerosis in Apoe (-/-) mice...
  74. ncbi An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats
    T Fushiki
    Department of Food Science and Technology, Faculty of Agriculture, Kyoto University, Japan
    J Nutr 122:2367-73. 1992
    ....
  75. pmc Pharmacological characterization of human incretin receptor missense variants
    Jean Philippe Fortin
    Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Pharmacol Exp Ther 332:274-80. 2010
    ..The extent to which abnormalities in GIP-R function may lead to physiological changes or affect drug sensitivity in selected populations (e.g., obese, diabetic individuals) remains to be further investigated...
  76. ncbi Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
    J J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Diabetologia 46:798-801. 2003
    In the isolated perfused pancreas, gastric inhibitory polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose concentrations, but in healthy humans no glucagonotropic effect of GIP has yet been reported...
  77. doi Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes
    J E Foley
    Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA
    Horm Metab Res 40:727-30. 2008
  78. pmc Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation
    Diane H Song
    Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA
    Gastroenterology 133:1796-805. 2007
    ..The purpose of these studies was to characterize the effects of GIP and its receptor (GIPR) in adipocyte development and signaling...
  79. ncbi GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, U K
    J Med Chem 49:1047-54. 2006
    ..These data demonstrate that fatty acid derivatized GIP peptides represent a novel class of long-acting stable GIP analogues for therapy of type 2 diabetes...
  80. pmc Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
    Minako Yamaoka-Tojo
    Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1 15 1 Kitasato, Minami Ku, Sagamihara, 252 0373, Japan
    Cardiovasc Diabetol 9:17. 2010
    ..In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role in MetS are largely unknown...
  81. pmc GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene
    Su Jin Kim
    Department of Cellular and Physiological Sciences and the Diabetes Research Group, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, Canada
    J Lipid Res 51:3145-57. 2010
    ..The lipogenic effects of GIP in the presence of insulin are therefore at least partially mediated by upregulation of adipocyte LPL gene transcription through a pathway involving PI3-K/PKB/AMPK-dependent CREB/TORC2 activation...
  82. ncbi Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
    J R Lindsay
    Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Coleraine, Northern Ireland, UK
    Diabet Med 22:654-7. 2005
    Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important insulinotropic hormones that enhance the insulin secretory response to feeding...
  83. ncbi Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    Jens Juul Holst
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
    Am J Physiol Endocrinol Metab 287:E199-206. 2004
    ..Because of this, analogs of GLP-1 or GLP-1 receptor activations are currently being developed for diabetes treatment, so far with very promising results...
  84. pmc The glucose-dependent insulinotropic polypeptide and glucose-stimulated insulin response to exercise training and diet in obesity
    Karen R Kelly
    Department of Pathobiology, Lerner Research Institute, Cleveland, OH 44195, USA
    Am J Physiol Endocrinol Metab 296:E1269-74. 2009
    ....
  85. pmc Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide
    Scott B Widenmaier
    Department of Cellular and Physiological Sciences and the Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    J Biol Chem 284:30372-82. 2009
    ..Inhibition of apoptosis by GIP is therefore mediated via a key pathway involving Akt-dependent inhibition of apoptosis signal-regulating kinase 1, which subsequently prevents the pro-apoptotic actions of p38 MAPK and JNK...
  86. ncbi Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?
    P R Flatt
    School of Biomedical Sciences, University of Ulster, Coleraine
    Diabet Med 25:759-64. 2008
    There is increasing realization that gastric inhibitory polypeptide (GIP) has actions outside of the pancreas and gastrointestinal tract...
  87. pmc Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diab
    Dhananjay Gupta
    Division of Endocrinology, Diabetes, and Metabolism and the Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Diabetes 59:1445-50. 2010
    ..Gene Bank blast for a homologous nucleotide sequence revealed the same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter sequence. We investigated the role of PPARgamma in GIP-R transcription...
  88. ncbi Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin
    C H McIntosh
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Endocrinology 140:398-404. 1999
    ....
  89. pmc Pleiotropic effects of GIP on islet function involve osteopontin
    Valeriya Lyssenko
    Diabetes and Endocrinology, Department of Clinical Sciences, University Hospital Malmo, Lund University, Malmo, Sweden
    Diabetes 60:2424-33. 2011
    ..Here we explored mechanisms that could explain the protective effects of GIP on islet function...
  90. ncbi Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK
    Biochem Biophys Res Commun 308:207-13. 2003
    ..The purpose of this article was to provide an overview of the biological effects of several GIP modifications and to highlight the potential of such analogues in the treatment of type 2 diabetes and obesity...
  91. ncbi A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice
    Norio Harada
    Dept Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Am J Physiol Endocrinol Metab 294:E61-8. 2008
    b>Gastric inhibitory polypeptide (GIP) is an incretin that potentiates insulin secretion from pancreatic beta-cells by binding to GIP receptor (GIPR) and subsequently increasing the level of intracellular adenosine 3',5'-cyclic ..
  92. ncbi The contribution of incretin hormones to the pathogenesis of type 2 diabetes
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Best Pract Res Clin Endocrinol Metab 23:433-41. 2009
    ..to defects in the secretion and insulinotropic action of the two main incretin hormones, namely gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)...
  93. ncbi Incretin and islet hormonal responses to fat and protein ingestion in healthy men
    Richard D Carr
    Novo Nordisk, Bagsvaerd, Denmark
    Am J Physiol Endocrinol Metab 295:E779-84. 2008
    ..We conclude that, whereas protein and fat release both incretin and islet hormones, the early GIP secretion after protein ingestion may be of primary importance to islet hormone secretion...
  94. ncbi QTL detection on porcine chromosome 12 for fatty-acid composition and association analyses of the fatty acid synthase, gastric inhibitory polypeptide and acetyl-coenzyme A carboxylase alpha genes
    G Munoz
    Departamento de Mejora Genética Animal, INIA, 28040 Madrid, Spain
    Anim Genet 38:639-46. 2007
    ..Similarly, gastric inhibitory polypeptide (GIP) and acetyl-coenzyme A carboxylase alpha (ACACA) were tested as candidate genes for the second ..
  95. ncbi On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
    Meena Asmar
    Department of Endocrinology, Hvidovre Hospital, Denmark
    Am J Physiol Endocrinol Metab 298:E614-21. 2010
    ..However, both insulin and GIP lower post-Intralipid FFA concentration, GIP probably via stimulation of insulin secretion, increasing FFA reesterification...
  96. ncbi Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test
    A P Gjesing
    Steno Diabetes Center, Hagedorn Research Institute, Gentofte, Denmark
    Diabetologia 54:103-10. 2011
    ..insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and gastric inhibitory polypeptide (GIP) among individuals carrying the high-risk rs7903146 TT genotype and low-risk CC genotype ..
  97. ncbi Effects of glucose-dependent insulinotropic peptide on osteoclast function
    Qing Zhong
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Am J Physiol Endocrinol Metab 292:E543-8. 2007
    ..These data are consistent with the hypothesis that GIP inhibits bone breakdown through a direct effect on osteoclast-resorptive activity and suggest one mechanism for the postprandial reduction in markers of bone breakdown...
  98. ncbi Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus
    Ronald H Clements
    Department of Surgery, Section of Gastrointestinal Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am Surg 70:1-4; discussion 4-5. 2004
    ..for demographics and fasting levels of the following: glucose, insulin, C-peptide, glucagon, cortisol, gastric inhibitory polypeptide (GIP), and glucagon-like peptide-1 (GLP-1)...
  99. ncbi Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors
    R J Bollag
    Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta 30912, USA
    Endocrinology 141:1228-35. 2000
    ..Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblast-like cells and that GIP modulates the function of these cells...
  100. ncbi Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)
    S A Hinke
    Department of Physiology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    Biochim Biophys Acta 1547:143-55. 2001
    ..Higher doses of GIP(1-14) and GIP(19-30) (100 pmol/min/100 g) also reduced blood glucose excursions...
  101. ncbi Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action
    Heying Zhou
    Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Biochem Biophys Res Commun 335:937-42. 2005
    Gut hormone gastric inhibitory polypeptide (GIP) stimulates insulin secretion from pancreatic beta-cells upon ingestion of nutrients...

Research Grants32

  1. Leptin and Neuroendocrine Gene Regulation in Obesity
    Judith Korner; Fiscal Year: 2005
    ..abstract_text> ..
  2. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2006
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. [unreadable] [unreadable]..
  3. Intestinal Triacylglycerol Metabolism and Energy Balance
    Chi Liang Eric Yen; Fiscal Year: 2013
    ..This work will both increase knowledge about a central component of metabolism as well as provide insights into potential therapies for addressing the obesity epidemic. ..
  4. Impact of Neprilysin on Islet Function
    Sakeneh Zraika; Fiscal Year: 2013
    ..These studies will delineate a novel role for islet and intestinal NEP in modulating [unreadable]-cell function, and will have significant implications for development of therapeutics to treat [unreadable]-cell dysfunction in diabetes. ..
  5. Role of Renal Dipeptidyl Peptidase IV
    EDWIN KERRY JACKSON; Fiscal Year: 2013
    ....
  6. Liver Glycogen in Control of Plasma Glucose
    Katarina Borer; Fiscal Year: 2009
    ..This study examines the role of liver glycogen depletion in this phenomenon and seeks to define the timing of meals and exercise and dietary carbohydrate content that are necessary to produce it. ..
  7. 8th International Symposium for VIP, PACAP & Related Peptides
    Victor May; Fiscal Year: 2007
    ..The 8th International Symposium aims to continue that information and technology transfer to accelerate new developments. [unreadable] [unreadable] [unreadable]..
  8. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2008
    ..abstract_text> ..
  9. Type 1 Diabetes TrialNet: Clinical Center at Columbia University
    Kevan Herold; Fiscal Year: 2007
    ..The Center will be able to coordinate with other centers in carrying out future trials of TrialNet. ..
  10. Role of Gastrin in the Pathogenesis of Colorectal Cancer
    Michael Wolfe; Fiscal Year: 2008
    ..The answers to these provocative hypotheses can only be achieved by gaining a thorough understanding of the molecular mechanisms by which gastrin exerts its trophic properties. ..
  11. Developmental, nutritional and hormonal reg. of Ghrelin
    Andrea Haqq; Fiscal Year: 2008
    ..Our studies should provide novel insights into the role of ghrelin and other hormones and adipocytokines in the regulation of body weight in both children with Prader-willi syndrome and normal children. ..
  12. Role of Insulin Regulation of Beta Cell Function in Vivo and in Vitro
    Allison Goldfine; Fiscal Year: 2008
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  13. Islet growth in NOD mice tolerant to autoimmune diabetes
    Kevan Herold; Fiscal Year: 2005
    ..By combining the expertise of the two Pl's to address the problems of islet autoimmunity and beta cell deficiency our proposal will test a combination strategy that may be useful in patients. ..
  14. Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
    Kevan C Herold; Fiscal Year: 2010
    ..Thus, this proposal will bridge both mechanistic studies and a clinical trial to develop a new treatment paradigm that may be beneficial to a large number of patients with T1DM. ..
  15. Role of Leptin in Islet Growth
    Rohit Kulkarni; Fiscal Year: 2008
    ..The proposed studies are aimed at the long-term goal of developing therapeutic strategies to prevent or delay the development of diabetes in obese individuals. [unreadable] [unreadable] [unreadable]..
  16. Combination of Anti-CD3 and Ag-Specific Immunotherapy
    Kevan Herold; Fiscal Year: 2005
    ..Furthermore, we propose that this effect of the combinatorial approach will allow us to maintain the clinical benefits by repeated administration of antigen. ..
  17. INSULIN & GLUCOSE SIGNALING PATHWAYS IN ISLET BETA CELLS
    Rohit Kulkarni; Fiscal Year: 2004
    ....
  18. Dissecting the Death Pathway in Islet Beta Cells
    Rohit Kulkarni; Fiscal Year: 2005
    ..abstract_text> ..
  19. Role of Exercise in the Endocrine Control of Feeding
    Katarina Borer; Fiscal Year: 2005
    ..The findings from these studies will extend theoretical understanding of energy regulation and provide insight for improved weight-loss strategies in obese individuals. ..
  20. Leptin modulation of insulin action in the islet b-cell
    Rohit Kulkarni; Fiscal Year: 2005
    ..abstract_text> ..
  21. Defintion of the Physiological Properties of GIP
    Michael Wolfe; Fiscal Year: 2007
    ..abstract_text> ..
  22. Mechanisms of ileal-induced weight loss
    APRIL STRADER; Fiscal Year: 2005
    ..Together these specific aims will help clarify the mechanisms underlying obesity surgery and may contribute to the development of more effective treatments for obesity. ..
  23. Leptin and Neuroendocrine Gene Regulation in Obesity
    Judith Korner; Fiscal Year: 2005
    ..Leibel and Dr. Wardlaw, are experienced in basic and clinical research. They are easily accessible, enthusiastic about my projects, and will facilitate my transition to status as an independent investigator. ..
  24. BRAIN ENERGY METABOLISM AND HYPOGLYCEMIA
    Patrick Boyle; Fiscal Year: 2003
    ..Better metabolic control, the key to the prevention of long-term complications of diabetes, will thus become more achievable. ..
  25. GPCR Variants as Genetic Determinants of Obesity
    Alan Kopin; Fiscal Year: 2009
    ..In Aim 3, combinations of anorexigenic, orexigenic and hedonic receptor variants will be assessed as potential synergistic or additive factors underlying the polygenic basis of obesity and/or other Look AHEAD study endpoints. ..
  26. Genetic Analysis of Feeding Behavior and Fat Deposition
    Alan Kopin; Fiscal Year: 2009
    ..Outliers will be characterized as described above. We anticipate that the proposed studies will identify novel genes relevant to the pathophysiology of human obesity. ..
  27. STRUCTURE/FUNCTION OF THE CCK-B/GASTRIN RECEPTOR
    Alan Kopin; Fiscal Year: 2004
    ....
  28. PHYSIOLOGY AND MOLECULAR DETERMINANTS OF DIABETES
    Allison Goldfine; Fiscal Year: 2004
    ....